News | December 17, 2023
Briefs: Torrent Pharmaceuticals and Laurus Synthesis
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Laurus Synthesis receives Form 483 with 5 observations from USFDA
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)